Russell Investments Group
ACTU

Russell Investments Group’s Actuate Therapeutics ACTU Stock Holding History

Russell Investments Group’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.6K Buy
584
+97
+20% +$402 ﹤0.01% 4017
2025
Q4 		$2.98K Hold
487
– – ﹤0.01% 3969
2025
Q3 		$3.26K Buy
+487
New +$3.53K ﹤0.01% 3949

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Russell Investments Group's ACTU Position: Q1 2026 in Review

Russell Investments Group increased its Actuate Therapeutics (ACTU) stake by 20% in Q1 2026, buying an estimated $402 and bringing the position to 584 shares worth $1.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4017.

Russell Investments Group first reported a position in ACTU in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.26K in Q3 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • Russell Investments Group held 584 shares of Actuate Therapeutics worth $1.6K as of Q1 2026.
  • Russell Investments Group bought 97 Actuate Therapeutics shares in Q1 2026, an estimated $402.
  • Actuate Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #4017 holding.
  • Russell Investments Group first reported a position in Actuate Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Russell Investments Group's Actuate Therapeutics position peaked at $3.26K in Q3 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.